X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Ferriprox™ (deferiprone) is a chelating agent with an affinity for ferric ion (iron III), being developed for the treatment of patients with transfusional iron overload due to thalassemia syndromes.
Lead Product(s): Deferiprone
Therapeutic Area: Genetic Disease Product Name: Ferriprox
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2023
Details:
Deferiprone is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is the generic version of Ferriprox®.
Lead Product(s): Deferiprone
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
USFDA has approved Ferriprox® (deferiprone) twice-a-day tablets for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
Lead Product(s): Deferiprone
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
Chiesi Group expands distribution network via acquisition for worldwide product rights.
Lead Product(s): Deferiprone
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CHIESI USA INC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
